← Back to Search

Transperineal vs Transrectal Biopsy for Infections(PREVENT2 Trial)

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY
Transperineal MRI-guided prostate biopsy +2 moreN/ARecruitingLed by Jim C Hu, MD MPHResearch Sponsored by Weill Medical College of Cornell University

PREVENT2 Trial Summary

This trial will compare the rate of infection and other complications after in-office transperineal MRI targeted prostate biopsy to the standard transrectal MRI targeted prostate biopsy.

Eligible Conditions
  • Infection

PREVENT2 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

PREVENT2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days post-biopsy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days post-biopsy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in infection adverse events, as measured on TRUS-BxQ
Secondary outcome measures
Change in adverse events, as measured on TRUS-BxQ
Change in patient-reported anxiety, as measured on a 0-10 Likert scale
Change in patient-reported pain and discomfort, as measured on a 0-10 Likert scale
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

PREVENT2 Trial Design

2Treatment groups
Active Control
Group I: TransrectalActive Control2 Interventions
Patients will receive a transrectal MRI-guided prostate biopsy.
Group II: TransperinealActive Control1 Intervention
Patients will receive a transperineal MRI-guided prostate biopsy.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,039 Previous Clinical Trials
1,325,866 Total Patients Enrolled
7 Trials studying Infections
8,468 Patients Enrolled for Infections
Patient-Centered Outcomes Research InstituteOTHER
535 Previous Clinical Trials
29,956,928 Total Patients Enrolled
4 Trials studying Infections
93,534 Patients Enrolled for Infections
Jim C Hu, MD MPHPrincipal InvestigatorWeill Cornell Medicine, NewYork-Presbyterian
3 Previous Clinical Trials
1,003 Total Patients Enrolled
1 Trials studying Infections
400 Patients Enrolled for Infections

Media Library

Transperineal MRI-guided prostate biopsy Clinical Trial Eligibility Overview. Trial Name: NCT04815876 — N/A
Infections Research Study Groups: Transrectal, Transperineal
Infections Clinical Trial 2023: Transperineal MRI-guided prostate biopsy Highlights & Side Effects. Trial Name: NCT04815876 — N/A
Transperineal MRI-guided prostate biopsy 2023 Treatment Timeline for Medical Study. Trial Name: NCT04815876 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many facilities are conducting this clinical research?

"Presently, 12 clinical sites are participating in this trial. These locations span from Elkins Park to Chicago with 10 other cities included as well. If you choose to join the study, it is beneficial to pick a clinic that is geographically close by so that travel time can be minimized."

Answered by AI

How many participants have been enrolled to partake in this experiment?

"In order to execute this trial, precisely 1302 participants that meet the required qualifications must volunteer. There are many medical centres across America where individuals can take part in this study; two such examples include Einstein Healthcare Network located in Elkins Park, Pennsylvania and University Hospitals Cleveland Medical Center situated in Cleveland, Ohio."

Answered by AI

Are there vacancies for this research opportunity still available?

"According to findings on clinicaltrials.gov, this experiment is still seeking volunteers; it was initially launched on June 24th 2021 and most recently modified on August 30th 2022."

Answered by AI
~42 spots leftby Feb 2024